Table 3. Details of treatment with... | American Society of Hematology

Table 3.

Details of treatment with rituximab and results

Patient no.	Interval from diagnosis to treatment, mo	No. of rituximab doses infused	Interval from treatment to response, d^3-150	Duration of response, mo	Relapse	Second treatment	Second remission	Second relapse	Third treatment	Third remission	Follow-up, mo
Responders
1	2.5	3	37	20.4	No	No	—	—	—	—	20.4
2	3.6	4	72	13.7	No	No	—	—	—	—	13.7
3	2.1	3	7	27.6	No	No	—	—	—	—	27.6
4	98.5	3	7	10.6	No	No	—	—	—	—	10.6
5	3.4	3	14	15.6	No	No	—	—	—	—	15.6
6	16.6	3	27	14.9	No	No	—	—	—	—	14.9
7	16.9	2	5	13.1	No	No	—	—	—	—	13.1
8	24.7	3	24	11.1	No	No	—	—	—	—	11.1
9	5.1	4	10	12.6	No	No	—	—	—	—	12.6
10	15.6	2	5	9.5	No	No	—	—	—	—	9.6
Responders who relapsed
11	10.6	3	6	7.3	Yes	Yes	Yes	—	—	—	14.5
12	26	3	38	8.1	Yes	Yes	Yes	Yes	Yes	Yes	24.6
13	91.7	2	5	9.7	Yes	Yes	Yes	—	—	—	12.8
Nonresponders
14	3.2	3	—	—	—	—	—	—	—	—	7.2
15	48.1	3	—	—	—	—	—	—	—	—	16.7
Median	15.6	3	12	12.6							13.7
Range	2.1-98.5	2-4	5-72	7.3-27.6							7.2-27.6

Patient no.	Interval from diagnosis to treatment, mo	No. of rituximab doses infused	Interval from treatment to response, d^3-150	Duration of response, mo	Relapse	Second treatment	Second remission	Second relapse	Third treatment	Third remission	Follow-up, mo
Responders
1	2.5	3	37	20.4	No	No	—	—	—	—	20.4
2	3.6	4	72	13.7	No	No	—	—	—	—	13.7
3	2.1	3	7	27.6	No	No	—	—	—	—	27.6
4	98.5	3	7	10.6	No	No	—	—	—	—	10.6
5	3.4	3	14	15.6	No	No	—	—	—	—	15.6
6	16.6	3	27	14.9	No	No	—	—	—	—	14.9
7	16.9	2	5	13.1	No	No	—	—	—	—	13.1
8	24.7	3	24	11.1	No	No	—	—	—	—	11.1
9	5.1	4	10	12.6	No	No	—	—	—	—	12.6
10	15.6	2	5	9.5	No	No	—	—	—	—	9.6
Responders who relapsed
11	10.6	3	6	7.3	Yes	Yes	Yes	—	—	—	14.5
12	26	3	38	8.1	Yes	Yes	Yes	Yes	Yes	Yes	24.6
13	91.7	2	5	9.7	Yes	Yes	Yes	—	—	—	12.8
Nonresponders
14	3.2	3	—	—	—	—	—	—	—	—	7.2
15	48.1	3	—	—	—	—	—	—	—	—	16.7
Median	15.6	3	12	12.6							13.7
Range	2.1-98.5	2-4	5-72	7.3-27.6							7.2-27.6

At least a 1.5 g/dL increase of hemoglobin. — indicates not applicable.